A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Trial Profile

A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Anaplastic large cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 20 Jul 2017 Planned End Date changed from 1 Apr 2020 to 23 Apr 2020.
    • 10 Jan 2017 Planned End Date changed from 1 May 2020 to 1 Apr 2020.
    • 10 Jan 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top